<DOC>
	<DOCNO>NCT00281021</DOCNO>
	<brief_summary>The purpose study determine potential benefit add Digoxin erlotinib ( Tarceva ) treatment patient non-small cell lung cancer .</brief_summary>
	<brief_title>Second Line Erlotinib ( Tarceva ) Plus Digoxin Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>Non-small cell lung cancer ( NSCLC ) account 80 % lung cancer case . The majority NSCLC patient advance disease time diagnosis , usually require treatment beyond standard first-line chemotherapy . Until recently , patient limit number option available second-line treatment NSCLC . In 2004 , erlotinib approved FDA second third-line treatment NSCLC . Erlotinib cancer chemotherapy medication slow growth spread cancer cell body . Recent research suggest medication call Digoxin sensitize cancer cell respond good chemotherapy . Digoxin normally use treat certain heart condition help heart beat strongly regularly approved FDA treatment NSCLC . Investigators hope subject response rate standard erlotinib therapy significantly improve addition Digoxin . The purpose study determine tumor response rate overall survival patient non-small cell lung cancer treat daily regimen erlotinib ( Tarceva ) plus Digoxin .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Digoxin</mesh_term>
	<criteria>diagnosis nonsmall cell lung cancer measurable evaluable disease primary tumor must document histopathic analysis disease recurrence occur great five year original diagnosis must biopsy proven treatment one prior chemotherapy regimen advance disease ( one additional prior regimen allow neoadjuvant , adjuvant , neoadjuvant plus adjuvant therapy ) serum creatinine &lt; 2mg/dl , calculate creatinine clearance &gt; 40cc/min use follow formula : ( 140age ) x WT ( kg ) x 0.85 ( female 0.72 ) x creatinine ( mg/dl ) . Tests must do within 28 day prior registration must CT scan ( chest &amp; abdomen ) within 4 week prior registration Zubrod performance status 03 woman pregnant nursing prior malignancy allow except : adequately treat basal cell squamous cell skin cancer , situ cervical cancer , adequately treated Stage I II cancer patient currently complete remission , cancer patient diseasefree 5 year history ventricular fibrillation , sinus node AV nodal disease , Wolff Parkinson White Syndrome , evidence congestive heart failure , chest pain exertion , hemodynamically significant life threaten cardiac arrhythmia , evidence prior myocardial infarction EKG . EKG must do within 28 day prior registration . A normal cardiac stress test within 182 day prior registration require patient 50 year old abnormal EKG history cardiac disease . hypersensitivity erlotinib and/or Digoxin abnormal level K , Mg , and/or Ca , condition cause abnormality ( e.g . malnutrition , severe diarrhea , prolong vomiting , dialysis , GI suction , untreated hypothyroidism , use diuretic , amphotericin B , steroid , antacid )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>Digoxin</keyword>
</DOC>